CTLA4 and breast cancer: Zheng et al. observed that cytotoxic T-lymphocyte antigen 4 (CTLA4) inhibitors increased infiltration of eosinophils into murine breast cancer models, leading to tumor vessel normalization and therapeutic efficacy [39].